Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Neurology and Neuroscience Reports
Published in: Current Neurology and Neuroscience Reports 9/2016

Open Access 01-09-2016 | Demyelinating Disorders (DN Bourdette and M Cameron, Section Editors)

Alemtuzumab for Multiple Sclerosis

Authors: Mark D. Willis, Neil P. Robertson

Published in: Current Neurology and Neuroscience Reports | Issue 9/2016

Login to get access

Abstract

Alemtuzumab is a humanised anti-CD52 monoclonal antibody approved for use in active, relapsing multiple sclerosis (MS). Administration results in a rapid depletion of circulating lymphocytes with a subsequent beneficial immune reconstitution. Early open-label experience and recent clinical trials have demonstrated a dramatic effect on relapse rates as well as a positive effect on radiological disease outcomes and disability measures. Despite a mechanism of action that results in profound lymphopaenia, opportunistic infections are rarely seen and no excess association with malignancy has been identified. However, acquired autoimmune disease (AID) is a common adverse event following treatment, necessitating rigorous monitoring in order to facilitate prompt detection and management. Despite this issue, a unique dosing schedule and durability of effect make alemtuzumab a welcome addition to currently available treatment options for MS.
Literature
1.
2.
Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476(7359):214–9.CrossRefPubMedPubMedCentral
3.
Patsopoulos NA, Barcellos LF, Hintzen RQ, et al. Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet. 2013;9(11):e1003926.CrossRefPubMedPubMedCentral
4.
Straus Farber R, Harel A, Lublin F. Novel agents for relapsing forms of multiple sclerosis. Annu Rev Med. 2016;67:309–21.CrossRefPubMed
5.
Coles A, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999;46(3):296–304.CrossRefPubMed
6.
Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet. 1994;344(8918):298–301.CrossRefPubMed
7.
Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819–28.CrossRefPubMed
8.
Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829–39.CrossRefPubMed
9.
Coles AJ, Compston DAC, Selmaj KW, et al. Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786–801.CrossRefPubMed
10.
Genzyme S. Lemtrada (R) (Alemtuzumab). Licenses. 2016.
11.
Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253(1):98–108.CrossRefPubMed
12.
Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain. 1996;119(Pt 1):225–37.CrossRefPubMed
13.
Cheetham GM, Hale G, Waldmann H, et al. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart. J Mol Biol. 1998;284(1):85–99.CrossRefPubMed
14.
Rowan WC, Hale G, Tite JP, et al. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol. 1995;7(1):69–77.CrossRefPubMed
15.
Watanabe T, Masuyama J, Sohma Y, et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol. 2006;120(3):247–59.CrossRefPubMed
16.
Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy. 2001;3(3):137–43.CrossRefPubMed
17.
Hale G, Rye PD, Warford A, et al. The glycosylphosphatidylinositol-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa. J Reprod Immunol. 1993;23(2):189–205.CrossRefPubMed
18.
Rao SP, Sancho J, Campos-Rivera J, et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One. 2012;7(6):e39416.CrossRefPubMedPubMedCentral
19.
Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis—a focus on alemtuzumab. Clin Immunol. 2012;142(1):25–30.CrossRefPubMed
20.
Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128(2):260–70.CrossRefPubMedPubMedCentral
21.
Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol. 2004;83(10):634–45.CrossRefPubMed
22.
Fox EJ. Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother. 2010;10(12):1789–97.CrossRefPubMed
23.
Kousin-Ezewu O, Azzopardi L, Parker RA, et al. Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology. 2014;82(24):2158–64.CrossRefPubMedPubMedCentral
24.
Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(3):298–304.CrossRefPubMed
25.
Thompson SA, Jones JL, Cox AL, et al. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30(1):99–105.CrossRefPubMed
26.
Robertson NP, Scolding NJ. Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab. Neurology. 2014;82(24):2150–1.CrossRefPubMed
27.
Cossburn MD, Harding K, Ingram G, et al. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology. 2013;80(1):55–61.CrossRefPubMed
28.
Havari E, Turner MJ, Campos-Rivera J, et al. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. Immunology. 2014;141(1):123–31.CrossRefPubMed
29.
Zhang X, Tao Y, Chopra M, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013;191(12):5867–74.CrossRefPubMed
30.
Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005;35(11):3332–42.CrossRefPubMed
31.
De Mercanti S, Rolla S, Cucci A, et al. Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. Neurol Neuroimmunol Neuroinflamm. 2016;3(1):e194.CrossRefPubMedPubMedCentral
32.
Freedman MS, Kaplan JM, Markovic-Plese S. Insights into the mechanisms of the therapeutic efficacy of alemtuzumab in multiple sclerosis. J Clin Cell Immunol. 2013. 4(4).
33.
Somerfield J, Hill-Cawthorne GA, Lin A, et al. A novel strategy to reduce the immunogenicity of biological therapies. J Immunol. 2010;185(1):763–8.CrossRefPubMed
34.
Coles A, Deans J, Compston A. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg. 2004;106(3):270–4.CrossRefPubMed
35.
Fox EJ, Sullivan HC, Gazda SK, et al. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol. 2012;19(2):307–11.CrossRefPubMed
36.
Hirst CL, Pace A, Pickersgill TP, et al. Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol. 2008;255(2):231–8.CrossRefPubMed
37.
Willis MD, Robertson NP. Alemtuzumab for the treatment of multiple sclerosis. Clin Risk Manag. 2015;31(11):525–34.CrossRef
38.
39.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52.CrossRefPubMed
40.
Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012;78(14):1069–78.CrossRefPubMed
41.
Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011;10(4):338–48.CrossRefPubMed
42.
Havrdova E, Arnold DL, Cohen JA et al. Durable efficacy of alemtuzumab on clinical outcomes over 5 years in treatment-naive patients with active relapsing-remitting multiple sclerosis with most patients not receiving treatment for 4 years: CARE-MS I extension study. In European Committee for Treatment and research in Multiple Sclerosis. Barcelona: 2015.
43.
Fox EJ, Arnold DL, Cohen JA et al. Durable efficacy of alemtuzumab on clinical outcomes over 5 years in CARE-MS II with most patients free from treatment for 4 years. In European Committee for Treatment and research in Multiple Sclerosis. Barcelona: 2015.
44.
Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010;133(Pt 8):2232–47.CrossRefPubMed
45.
Barkhof F, Cohen JA, Coles AJ et al. Alemtuzumab slows brain volume loss over 5 years in patients with active relapsing-remitting multiple sclerosis with most patients not receiving treatment for 4 years: CARE MS I and II extension study. In European Committee for Treatment and research in Multiple Sclerosis. Barcelona: 2015.
46.
Arnold DL, Traboulsee A, Cohen JA et al. Alemtuzumab demonstrates durable reduction of MRI activity over 5 years in CARE-MS I with the majority of patients treatment-free for 4 years. In European Committee for Treatment and research in Multiple Sclerosis. Barcelona: 2015.
47.
Traboulsee A, Cohen JA, Coles AJ et al. Alemtuzumab demonstrates durable reduction of MRI activity over 5 years in CARE-MS II with most patients free from treatment for 4 years. In European Committee for Treatment and research in Multiple Sclerosis. Barcelona: 2015.
48.
Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry. 2015;86(2):208–15.CrossRefPubMed
49.
Willis MD, Harding KE, Pickersgil TP et al. Alemtuzumab for multiple sclerosis: long term follow-up in a multi-centre cohort. Mult Scler J. 2015. pii: 1352458515614092. (Epub ahead of print).
50.
Brown JWL, Tuohy O, Kousin-Ezewu O et al. Alemtuzumab in multiple sclerosis: long-term follow-up of the early cohorts. In: European Committee for Treatment and research in Multiple Sclerosis. Barcelona: 2015.
51.
Daniels GH, Vladic A, Brinar V, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab. 2014;99(1):80–9.CrossRefPubMed
52.
Jones JL, Thompson SA, Loh P, et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci U S A. 2013;110(50):20200–5.CrossRefPubMedPubMedCentral
53.
Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354(9191):1691–5.CrossRefPubMed
54.
Cossburn MD, Pace AA, Jones J, et al. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77(6):573–9.CrossRefPubMed
55.
Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood. 2011;118(24):6299–305.CrossRefPubMed
56.
Jones JL, Coles AJ. Mode of action and clinical studies with alemtuzumab. Exp Neurol. 2014;262 Pt A:37–43.CrossRefPubMed
57.
Jones JL, Phuah CL, Cox AL, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest. 2009;119(7):2052–61.PubMedPubMedCentral
58.
Azzopardi L, Thompson SA, Harding KE, et al. Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(7):795–8.CrossRefPubMed
59.
Rau D, Lang M, Harth A, et al. Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis—report of two cases. Int J Mol Sci. 2015;16(7):14669–76.CrossRefPubMedPubMedCentral
60.
Turner MJ, Lamorte MJ, Chretien N, et al. Immune status following alemtuzumab treatment in human CD52 transgenic mice. J Neuroimmunol. 2013;261(1–2):29–36.CrossRef
61.
Miller T, Habek M, Coles A et al. Analysis of data from RRMS alemtuzumab-treated patients in the clinical program to evaluate incidence rates of malignancy. In Joint Meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple Sclerosis. Boston, MA, USA: 2014.
62.
Lecumberri B, Arnold DA, Cohen JA et al. Detection of thyroid malignancies in alemtuzumab-treated patients in the multiple sclerosis clinical development program. In European Committee for Treatment and Research in Multiple Sclerosis. Barcelona: 2015.
63.
Ibitoye R, Wilkins A. Thyroid papillary carcinoma after alemtuzumab therapy for MS. J Neurol. 2014;261(9):1828–9.CrossRefPubMed
64.
Pace AA, Zajicek JP. Melanoma following treatment with alemtuzumab for multiple sclerosis. Eur J Neurol. 2009;16(4):e70–1.CrossRefPubMed
65.
Lemtrada. Summary of product characteristics. European Medicines Agency.
66.
Achiron A, Chambers C, Fox EJ et al. Pregnancy outcomes in patients with active RRMS who received alemtuzumab in the clinical development program. In European Committee for Treatment and Research in Multiple Sclerosis. Barcelona: 2015.
67.
Margolin DH, Rizzo MA, Smith G, et al. Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: a CARE-MS substudy. J Neurol Sci. 2013;333(Supplement 1):e375–6.CrossRef
68.
Wray S, Arnold DL, Cohen JA et al. Herpes infection risk reduced with acyclovir prophylaxis after alemtuzumab. In Consortium of Multiple Sclerosis Centers Annual Meeting. Orlando, FL, USA: 2013.
69.
70.
Metadata
Title
Alemtuzumab for Multiple Sclerosis
Authors
Mark D. Willis
Neil P. Robertson
Publication date
01-09-2016
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 9/2016
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-016-0685-y

Other articles of this Issue 9/2016

Current Neurology and Neuroscience Reports 9/2016 Go to the issue

Behavior (H Kirshner, Section Editor)

Anosognosia in Dementia

Neuro-Oncology (LE Abrey, Section Editor)

Chemotherapy-Related Neurotoxicity

Behavior (H Kirshner, Section Editor)

A Neuropsychological Perspective on Abstract Word Representation: From Theory to Treatment of Acquired Language Disorders

Critical Care (SA Mayer, Section Editor)

Hypothermia for Increased Intracranial Pressure: Is It Dead?

Epilepsy (CW Bazil, Section Editor)

Pharmacological Treatment of Drug-Resistant Epilepsy in Adults: a Practical Guide

Critical Care (SA Mayer, Section Editor)

ICU Management of the Potential Organ Donor: State of the Art